India: LKS advises Krsnaa Diagnostics

IFLR is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement


India: LKS advises Krsnaa Diagnostics

Sponsored by

24LakshmikumaranIndia.png

Lakshmikumaran and Sridharan advised Krsnaa Diagnostics Limited, a listed entity on its acquisition of 23.35% stake in Apulki Healthcare Private Limited. Apulki specialises in operating cancer and cardiac care hospitals in public-private partnership (PPP) mode.

Lakshmikumaran and Sridharan advised Krsnaa Diagnostics Limited, a listed entity on its acquisition of 23.35% stake in Apulki Healthcare Private Limited. Apulki specialises in operating cancer and cardiac care hospitals in public-private partnership (PPP) mode.

The firm’s role included conducting legal due diligence on Apulki, drafting and review of transaction documents, and strategic advisory on tax implications.

The corporate due diligence team consisted of Noorul Hassan, Partner, Shipra Verma, Principal Associate, Aishwarya Narasimhan, Associate and Krishna Chandak, Consultant.

Additionally, Sameer Avasarala, Principal Associate and Aryashree Kunhambu, Associate assisted with intellectual property and data protection aspects of the due diligence.

The transaction team was led by Noorul Hassan along with Shipra Verma and Kumar Panda, Principal Associate. Direct tax advisory was provided by Mr. Sudin Sabnis, Partner, Lokesh Gandhi, Associate and Deah Kapoor, Consultant.

Gift this article